Live Feeds
● LIVE Updated 1h ago · 11 sources tracked

Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

Amgen announced that its drug Imdelltra combined with AstraZeneca's Imfinzi cut the risk of death by 58 percent in patients with an aggressive form of lung cancer. Presented at the European Society for Medical Oncology presidential symposium and published in The New England Journal of Medicine, the Phase 3 DeLLphi-305 trial showed the combination extended median overall survival to 21.1 months compared to 12.7 months with Imfinzi alone. Nearly 80 percent of patients receiving the combination were alive at one year, while progression-free survival more than tripled.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (11)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Amgen announced that IMDELLTRA combined with AstraZeneca's IMFINZI reduced the risk of death by 58 percent as a first-line maintenance treatment for extensive stage small cell lung cancer.
  • ✓ The Phase 3 DeLLphi-305 results were presented in the ESMO Presidential Symposium and published in The New England Journal of Medicine.
  • ✓ The combination treatment extended median overall survival to 21.1 months compared with 12.7 months for IMFINZI alone.
  • ✓ Nearly 80 percent of patients were alive at one year when treated with the drug combination, versus 53 percent with IMFINZI alone.
🛡️ Source Corroboration: 11 independent reporting domains (100% confidence) ⏱ Read time: ~2 min

What changed

Amgen released interim Phase 3 clinical trial data for the Imdelltra and Imfinzi combination treatment.

Live updates

  1. Amgen Drug Combo Cuts Lung Cancer Death Risk by 58%

    Amgen announced that its drug Imdelltra combined with AstraZeneca's Imfinzi cut the risk of death by 58 percent in patients with an aggressive form of lung cancer. Presented at the European Society for Medical Oncology presidential symposium and published in The New England Journal of Medicine, the Phase 3 DeLLphi-305 trial showed the combination extended median overall survival to 21.1 months compared to 12.7 months with Imfinzi alone. Nearly 80 percent of patients receiving the combination were alive at one year, while progression-free survival more than tripled.

    Why it matters

    Small cell lung cancer is an aggressive disease with historically poor prognoses and limited treatment breakthroughs. The new clinical trial results represent a potential shift in first-line maintenance therapy for extensive-stage patients. Longer follow-up data from a separate study also showed median overall survival exceeding 37 months.

    What is confirmed

    • Amgen announced that IMDELLTRA combined with AstraZeneca's IMFINZI reduced the risk of death by 58 percent as a first-line maintenance treatment for extensive stage small cell lung cancer.
    • The Phase 3 DeLLphi-305 results were presented in the ESMO Presidential Symposium and published in The New England Journal of Medicine.
    • The combination treatment extended median overall survival to 21.1 months compared with 12.7 months for IMFINZI alone.
    • Nearly 80 percent of patients were alive at one year when treated with the drug combination, versus 53 percent with IMFINZI alone.

    What to watch next

    • Regulatory submissions and approvals for the drug combination in first-line extensive stage small cell lung cancer
    • Further developments and long-term survival data from ongoing clinical studies
    Sources used for this update (11)
    1. www.cnbc.com — Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer
    2. CNBC — Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer
    3. Amgen — IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
    4. NBC News — ‘Practice-changing’ new lung cancer immunotherapy improves survival
    5. Fierce Pharma — ESMO: Amgen’s Imdelltra drives massive survival benefit in ‘watershed moment’ for small cell lung cancer
    6. Reuters — Amgen drug combined with immunotherapy extends survival in lung cancer trial
    7. Bloomberg.com — Amgen, Astra Drug Duo Boosts Survival for Deadly Lung Cancer
    8. www.amgen.com — IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH ...
    9. www.healthandme.com — Amgen & AstraZeneca's New Treatment Combination Cuts Advanced Lung Cancer Death Risk By 58% In Trial | Health and Me
    10. www.europesays.com — Amgen's Imdelltra combo cuts risk of death by 58% in lung ...
    11. globalmarketnews.com — Amgen Drug Combination Cuts Death Risk 58% in Lung Cancer ...
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community